← board
CGC
distress 9/10 · high distress / dilution risk$0.90-1%today-53% from 52w high
Revenue
$285M
Liquidity
$365M
Runway
0.7 yrs
Shares 1y
+76%
Price & events
-23.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.1%
1D
-2.9%
1W
-4.9%
1M
-26.2%
3M
-24.4%
6M
-23.1%
1Y
-89.0%
2Y
-99.5%
5Y
-99.7%
All
Overview
- Market Cap
- $379.98M
- Enterprise Value
- $232.42M
- Volume
- 1.16M
- 52 Week Range
- $0.86 – $1.92
- Total Shares
- 422.15M
- Float Shares
- 421.75M
- Short %
- 5.63%
- % Held by Insiders
- 0.25%
- % Held by Institutions
- 7.90%
- RVOL
- 0.27x
- Beta
- 2.42
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 7
- 2026-08-07Estimated 45%earningsEarningsEarnings releaseyahoo
- June 15, 2026regulatory submissionFiled (NDA/BLA)Filing of restated financial statements for fiscal years 2024 and 2025 and Q4 FY2026 resultsSEC 8-K
- 2026-05-15withdrawalNon-reliance on previously issued financial statements due to accounting error in warrant classificationSEC 8-K
- 2026-03-16partnershipCompleted acquisition of MTL Cannabis to create Canada's leading medical cannabis business by revenue.SEC 8-K
- 2025-12-14partnershipArrangement to acquire MTL Cannabis Corp. for ~38M shares and C$17M cash.SEC 8-K
- 2025-08-29partnershipEntered into equity distribution agreement with BMO Capital Markets Corp. and BMO Nesbitt Burns Inc. for at-the-market offering up to $200MSEC 8-K
- 2025-02-28partnershipEntered equity distribution agreement with BMO Capital MarketsSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $1 (+37% upside) · 1 analysts
- 2025-11-10BenchmarkSell → Hold
- 2025-03-27Zuanic & AssociatesNeutral
- 2024-07-09Piper SandlerUnderweight
Competitors
- none identified
Recent news
- 2026-07-17Canopy Growth (NASDAQ: CGC) seeks approval for share consolidation, pay votes - Stock Titan
- 2026-07-08Is Canopy Growth Stock Finally Worth Buying After Losing 99% of Its Value? - Yahoo Finance
- 2026-06-29Tax-related share sale by Canopy Growth (CGC) director after RSU vesting - Stock Titan
- 2026-06-22Canopy Growth (CGC) director receives 108K-share RSU grant - Stock Titan
- 2026-06-22Canopy Growth (CGC) officer gains major equity awards, sells shares to cover tax - Stock Titan
- 2026-06-22Director at Canopy Growth (CGC) receives 108K-share restricted stock grant - Stock Titan
- 2026-06-22108K-share RSU award to Canopy Growth (CGC) director Theresa Yanofsky - Stock Titan
- 2026-06-16CGC Q4 Earnings Call Focuses on EBITDA Path - Yahoo Finance
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.